Logo for Blueprint Medicines Corp

Blueprint Medicines Investor Relations Material

Latest events

Logo for Blueprint Medicines Corp

Q4 2023

Blueprint Medicines
Logo for Blueprint Medicines

Q4 2023

15 Feb, 2024
Logo for Blueprint Medicines

Q3 2023

26 Oct, 2023
Access the full event backlog
Slides, Transcripts, and Reports from 9,000+ public companies

Latest reports from Blueprint Medicines Corp

Access all reports
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. It focuses on the discovery, development, and commercialization of small molecule therapies for patients with diseases caused by genetic mutations. The company's pipeline products include, among other, BPX-501 that targets Caskin 1; BPX-701 that is involved in targeting patients with Ras (RAS) inhibitor-refractory or -intolerant melanoma; BPX-601 that is involved in targeting basal cell carcinoma; BPX-302 that targets Bcr/Abl fusion proteins; and BPX-401 that targets NY-ESO-1.